Marker sequences for breast cancer and the use thereof
AssigneeProtagen AG
InventorsAngelika Lüking, Axel Kowald, Annabel Höpner, Christian Scheer, Heidelinde Fiegl, Günter Daxenbichler
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for identifying marker sequences for breast cancer, the marker sequences identified with the aid of this method and diagnostic use thereof, diagnostic devices containing marker sequences for breast cancer, in particular an arrangement and a protein array, and use thereof. The invention also relates to method for the screening of potential active agents for the treatment and prevention of breast cancer by means of these marker sequences.
Claims17
1-13. (canceled)
A method for identifying marker sequences for breast cancer, comprising
- a. identifying marker sequence candidates for breast cancer in that a support, on which at least 1,000 different proteins are immobilised, is brought into contact with a serum sample from a patient with breast cancer and proteins that demonstrate an interaction with the serum are identified (marker sequence candidates), and
- b. determining the interaction of one or more marker sequence candidates from a. with the serum from female patients with breast cancer is compared with
- the interaction of the marker sequence candidate(s) from a. with the serum from female patients with benign changes and
- the interaction of the marker sequence candidate(s) from a. with the serum of healthy control individuals, and
- c. identifying marker sequences that demonstrate an interaction with the serum from female patients with breast cancer that is different compared with the interaction with the serum from female patients with benign changes and the serum from healthy control individuals, and wherein the evaluation is performed by means of statistical analysis.
A method for the early detection, diagnosis, prognosis, therapy control and/or aftercare in the case of breast cancer, wherein
- a.) a marker sequence or a number of marker sequences selected from the group comprising sequences SEQ ID No. 1-1473 and partial sequences of SEQ ID No. 1-1473 with at least 90%, preferably 95%, of the length of the sequences SEQ ID No. 1-1473 and homologues of SEQ ID No. 1-1473 and partial sequences thereof with an identity of at least 95%, preferably 98% or more, to the corresponding nucleic acid and/or protein sequences and sequences coded by SEQ ID No. 1-491, partial sequences thereof and homologues thereof is/are applied to a support,
- b.) is/are brought into contact with bodily fluid or tissue sample from a patient, and
- c.) an interaction of the bodily fluid or the tissue sample with the marker sequence(s) for breast cancer a from a.) is detected.
Dependencies are inferred from the claim text.